All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Opthea

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Opthea Reports Positive Phase 2a Trial Results of OPT-302 in Diabetic Macular Edema

Contact the Supplier

Lead Product(s): OPT-302,Aflibercept

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

The trial met the prespecified primary efficacy endpoint with 52.8% of patients (95% CI 41-64%) achieving ≥ 5 letters gain in Best Corrected Visual Acuity (BCVA) at week 12.